DE69228127D1 - Therapie des zentralnervensystems mit genetisch modifizierten zellen - Google Patents

Therapie des zentralnervensystems mit genetisch modifizierten zellen

Info

Publication number
DE69228127D1
DE69228127D1 DE69228127T DE69228127T DE69228127D1 DE 69228127 D1 DE69228127 D1 DE 69228127D1 DE 69228127 T DE69228127 T DE 69228127T DE 69228127 T DE69228127 T DE 69228127T DE 69228127 D1 DE69228127 D1 DE 69228127D1
Authority
DE
Germany
Prior art keywords
genetically modified
modified cells
cells
system therapy
veneer system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69228127T
Other languages
English (en)
Other versions
DE69228127T2 (de
Inventor
Fred Gage
Theodore Friedmann
Michael Rosenberg
Jon Wolff
Malcolm Schinstine
Michael Kawaja
Jasodhara Ray
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of DE69228127D1 publication Critical patent/DE69228127D1/de
Application granted granted Critical
Publication of DE69228127T2 publication Critical patent/DE69228127T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/33—Fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/16—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with reduced pteridine as one donor, and incorporation of one atom of oxygen (1.14.16)
    • C12Y114/16002—Tyrosine 3-monooxygenase (1.14.16.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
DE69228127T 1991-11-15 1992-11-13 Therapie des zentralnervensystems mit genetisch modifizierten zellen Expired - Lifetime DE69228127T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US79289491A 1991-11-15 1991-11-15
PCT/US1992/009896 WO1993010234A1 (en) 1991-11-15 1992-11-13 Therapy of central nervous system by genetically modified cells
CA002095300A CA2095300C (en) 1991-11-15 1993-04-30 Use of genetically modified cells to treat defects, disease or damage of the central nervous system
JP5136554A JPH06329559A (ja) 1991-11-15 1993-05-14 遺伝子的に修飾された細胞を移植して中枢神経系における欠陥、疾病、あるいは損傷を治療するための方法

Publications (2)

Publication Number Publication Date
DE69228127D1 true DE69228127D1 (de) 1999-02-18
DE69228127T2 DE69228127T2 (de) 1999-09-02

Family

ID=27169416

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69228127T Expired - Lifetime DE69228127T2 (de) 1991-11-15 1992-11-13 Therapie des zentralnervensystems mit genetisch modifizierten zellen

Country Status (9)

Country Link
EP (1) EP0625195B1 (de)
JP (1) JPH06329559A (de)
AT (1) ATE175442T1 (de)
CA (1) CA2095300C (de)
DE (1) DE69228127T2 (de)
DK (1) DK0625195T3 (de)
ES (1) ES2126606T3 (de)
GR (1) GR3029362T3 (de)
WO (1) WO1993010234A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6103226A (en) * 1994-08-12 2000-08-15 Arch Development Corporation Genetically engineered cells that produce produce L. Dopa
US6294383B1 (en) 1994-11-08 2001-09-25 The Mclean Hospital Corporation Porcine neural cells and their use in treatment of neurological deficits due to neurodegenerative diseases
US6204053B1 (en) 1994-11-08 2001-03-20 Diacrin, Inc. Porcine cortical cells and their use in treatment of neurological deficits due to neurodegenerative diseases
WO1996022112A1 (en) 1995-01-17 1996-07-25 Genetic Therapy, Inc. Delivery of therapeutic agents by gene therapy
US5753505A (en) * 1995-07-06 1998-05-19 Emory University Neuronal progenitor cells and uses thereof
AU762472B2 (en) 1998-03-13 2003-06-26 University Of British Columbia, The Therapeutic chemokine receptor antagonists
CA2245224A1 (en) 1998-08-14 2000-02-14 Jiang-Hong Giong Chemokine receptor antagonists and chemotherapeutics
CA2305787A1 (en) 2000-05-09 2001-11-09 The University Of British Columbia Cxcr4 antagonist treatment of hematopoietic cells
US6444205B2 (en) 1998-09-30 2002-09-03 Diacrin, Inc. Transplantation of neural cells for the treatment of chronic pain or spasticity
US20040120891A1 (en) 1998-12-21 2004-06-24 Craig Hill Compounds for intracellular delivery of therapeutic moieties to nerve cells
US6652864B1 (en) 1998-12-21 2003-11-25 Asilomar Pharmaceuticals, Inc. Compounds for intracellular delivery of therapeutic moieties to nerve cells
AU780754B2 (en) * 1999-03-04 2005-04-14 Revivicor Inc Genetic modification of somatic cells and uses thereof
WO2001075094A1 (en) * 2000-04-04 2001-10-11 Thomas Jefferson University Application of myeloid-origin cells to the nervous system
US7378098B2 (en) 2000-04-12 2008-05-27 The University Of British Columbia CXC chemokine receptor 4 agonist peptides
US20050059584A1 (en) 2002-08-16 2005-03-17 Ahmed Merzouk Novel chemokine mimetics synthesis and their use
US7368425B2 (en) 2006-03-24 2008-05-06 Chemokine Therapeutics Corp. Cyclic peptides for modulating growth of neo-vessels and their use in therapeutic angiogenesis
US20030124095A1 (en) 2001-12-31 2003-07-03 Regents Of The University Of California Methods for therapeutic use of brain derived neurotrophic factor in the entorhinal cortex
KR101226702B1 (ko) * 2010-10-08 2013-01-25 충북대학교 산학협력단 인간 콜린 아세틸트랜스퍼라아제를 발현하는 인간 신경줄기세포 및 이의 용도
MX2021000644A (es) 2018-07-18 2021-08-19 Manzanita Pharmaceuticals Inc Conjugados para suministrar un agente contra el cancer a las celulas nerviosas, metodos de uso y metodos para la elaboracion de los mismos.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3015383B2 (ja) * 1987-09-11 2000-03-06 ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ 形質導入した線維芽およびそれらの使用
US5082670A (en) * 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
US6511823B1 (en) * 1990-08-20 2003-01-28 American Cyanamid Corporation Heparin binding neurotrophic factor gene sequence
AU9076191A (en) * 1990-11-21 1992-06-25 Massachusetts Institute Of Technology Mice having beta 2 microglobulin gene disruption

Also Published As

Publication number Publication date
EP0625195B1 (de) 1999-01-07
CA2095300C (en) 2002-06-25
JPH06329559A (ja) 1994-11-29
GR3029362T3 (en) 1999-05-28
EP0625195A1 (de) 1994-11-23
CA2095300A1 (en) 1994-10-31
ATE175442T1 (de) 1999-01-15
WO1993010234A1 (en) 1993-05-27
ES2126606T3 (es) 1999-04-01
DK0625195T3 (da) 1999-08-30
DE69228127T2 (de) 1999-09-02

Similar Documents

Publication Publication Date Title
DE69228127T2 (de) Therapie des zentralnervensystems mit genetisch modifizierten zellen
DE68929077T2 (de) Transplantieren von genetisch modifizierten zellen zur behandlung von krankheiten des zentralen nervensystems
PT923293E (pt) Tratamento da diarreia
NO844579L (no) Enzymresistente immunomodulerende peptider.
DK0918848T3 (da) Fremgangsmåder til at behandle kræftsygdomme og patogene infektioner ved anvendelse af antigenpræsenterende celler påfyldt med RNA
CA2265464A1 (en) Therapy for .alpha.-galactosidase a deficiency
SE8000435L (sv) N-bensylimidazoler med selektivt inhiberande verkan pa tromboxansyntetasenzymet jemte farmaceutiska beredningar innehallande sadana n-bensylimidazoler och sett for deras framstellning
ATE224708T1 (de) Antitumorale 2-aminocarbonyl-1,2-bis (methylsulfonyl)-1-(substituierte) hydrazine
DK0768886T3 (da) Endothelforingseffekter og behandling af vasospastiske lidelser
BR8100869A (pt) Processo para o isolamento de substancia solida de caldo de cultura de salinomicina e substancia solida de caldo de cultura de salinomicina
FI891020A0 (fi) Menetelmä proteaasi-inhibiittoriaktiivisuutta omaavien egliinimutanttien valmistamiseksi
Dubbelman et al. Photodynamic inactivation of L929 cells after treatment with hematoporphyrin derivative
GR3003950T3 (de)
Prince Commentary on four papers on psychiatry and religion.
JPS6464672A (en) Impact medical treatment device
RU95120122A (ru) Способ лечения хронического простатита
RU97107873A (ru) Способ повышения иммунных свойств переливаемой аутокрови
NO900044L (no) Hemorroidale, andre blandinger og metoder for behandling.
BG49441A1 (en) 1- phenil- n- (2- chlorethylcarbamoil)- 7, 8- dimetoxy- 2, 3, 4, 5- tetrahydro- 1h- 3- benzazepini and method for their preparation
RU96124549A (ru) Способ лечения псориаза
UA38258A (uk) Засіб лікування гіпертонічної хвороби, асоційованої з ішемічною хворобою серця

Legal Events

Date Code Title Description
8364 No opposition during term of opposition